-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Radiotherapy continues to play an important role in the treatment of early breast cancer , which can reduce the overall recurrence rate and mortality of patients.
Breast Cancer For patients with early breast cancer, compared with whole breast radiotherapy (WBI), accelerated local breast radiotherapy (APBI) with intraoperative radiotherapy is associated with a higher rate of recurrence of ipsilateral breast tumors (IBTR)
Recently published in The Lancet sub-Journal " Lancet Oncolog on y" article " Intraoperative irradiation for Early Breast Cancer (ELIOT): Long-Term Recurrence and Survival Outcomes from A SINGLE-Center, randomized, Phase 3 Trial an EQUIVALENCE ", The long-term recurrence rate and survival prognosis of patients in the ELIOT trial were evaluated .
The Lancet Oncolog Lancet Oncolog Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial evaluated the long-term recurrence rate and survival prognosis of patients in the ELIOT trial
The ELIOT trial is a single-center, randomized phase 3 trial carried out in Italy.
From November 20, 2000 to December 27, 2007, a total of 1305 patients were recruited, of which 654 were assigned to the WBI group and 651 were assigned to the ELIOT group.
Cumulative incidence of IBTR in both groups
Cumulative incidence of IBTR in both groupsAfter a median follow-up of 12.
IBTR occurred in 86 patients (7%), of which 70 (11%) were in the ELIOT group and 16 (2%) were in the WBI group.
There was no significant difference in mortality between the two groups
Overall survival rate of the two groups
Overall survival rate of the two groupsIn the ELIOT group, the overall survival rates at 5, 10, and 15 years were 96.
In the ELIOT group, the overall survival rates at 5, 10, and 15 years were 96.
The long-term results of the trial confirmed that the IBTR rate of the ELIOT group was significantly higher than that of the WBI group, but there was no significant difference in overall survival rate.
Original source:
Orecchia Roberto, Veronesi Umberto, Maisonneuve Patrick et al.
org/10.
1016/S1470-2045(21)00080-2" target="_blank" rel="noopener">Intraoperative irradiation for early breast cancer (ELIOT ): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial in this message
